Rosuvastatin treatment resulted in lower levels of ET-1, ADMA, and lipids, and fewer adverse reactions compared to atorvastatin in elderly patients with CAD and hyperlipidemia (p<0.05).
Observational (n=216)
Does rosuvastatin improve serum ET-1 and ADMA levels compared to atorvastatin in elderly patients with coronary artery disease combined with hyperlipidemia?
In elderly patients with CAD and hyperlipidemia, rosuvastatin demonstrated superior improvements in endothelial function, immune markers, and lipid profiles compared to atorvastatin, alongside a better safety profile.
p-value: p=<0.05
Abstract To investigate the effects of treatment with rosuvastatin and atorvastatin on serum endothelin-1 (ET-1) and asymmetrical dimethylarginine (ADMA) in elderly patients with coronary artery disease combined with hyperlipidemia. The data of 216 elderly patients with coronary artery disease combined with hyperlipidemia received during January 2023–December 2023 were retrospectively analyzed. Based on the different treatment programs, they were divided into atorvastatin group ( n = 108) and rosuvastatin group ( n = 108), and then before treatment, after 30d, 60d, 90d and 120d the two groups of patients were compared with the indicators of vascular endothelial function, immune function, blood lipid level, and adverse reactions. Comparison of the indicators of vascular endothelial function, immune function, and lipid level between the two groups of patients before treatment, p > 0.05. After 30d and 60d of treatment, the level of ET-1, ADMA, and visceral adipose tissue-derived serine protease inhibitor (Vaspin) was lower in the rosuvastatin group than in the atorvastatin group, p < 0.05. Immune functions such as cluster of differentiation 4 positive (CD4+)/cluster of differentiation 3 positive (CD3+)/CD4+ and cluster of differentiation 8 positive (CD8+) ratios and other immune functions were higher than those in the atorvastatin group, p < 0.05. Patients in the rosuvastatin group had lower lipid levels such as total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) than those in the atorvastatin group, p < 0.05. The incidence of adverse reactions such as loss of appetite, headache, dizziness, fatigue, constipation, etc. in patients in the rosuvastatin group was lower than that in the atorvastatin group, p < 0.05. Rosuvastatin compares favorably with atorvastatin in improving vascular endothelial function, improving immune function, lowering lipid levels, and mitigating adverse effects in elderly patients with coronary artery disease combined with hyperlipidemia.
Ting Xu (Thu,) conducted a observational in coronary artery disease combined with hyperlipidemia (n=216). rosuvastatin vs. atorvastatin was evaluated on serum endothelin-1 (ET-1) and asymmetrical dimethylarginine (ADMA) (p=<0.05). Rosuvastatin treatment resulted in lower levels of ET-1, ADMA, and lipids, and fewer adverse reactions compared to atorvastatin in elderly patients with CAD and hyperlipidemia (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: